ArticleScientific reports2017
Development and validation of a high throughput whole blood thrombolysis plate assay.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Purification, biochemical characterization and fibrinolytic potential of proteases produced by bacteria of the genus Bacillus: a systematic literature review.Archives of microbiology · 2022Pooled it
- What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies.Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2019Pooled it
- Engineered nanoconjugates for simultaneous detection and degradation of stroke-associated microthrombi.Theranostics · 2026Article
- M1 protein from group ABlood vessels, thrombosis & hemostasis · 2025Article
- Enhancing Thrombolysis Safety in Post-Acute Ischemic Stroke with Tissue Plasminogen Activator-Associated Microparticles.ACS nano · 2025Article
- Halo fluorescence fibrinolysis test: a novel quantitative assay to evaluate fibrinolysis on established plasma clots.Research and practice in thrombosis and haemostasis · 2025Article
- Article
- A facultative plasminogen-independent thrombolytic enzyme from Sipunculus nudus.Nature communications · 2025Article
- Recombinant chymase inhibits fibrinolysis induced by endogenous plasmin in clotted human blood.Frontiers in immunology · 2025Article
- Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives.International journal of molecular sciences · 2024Article
- Redox-responsive peptide-based complex coacervates as delivery vehicles with controlled release of proteinous drugs.Communications chemistry · 2023Article
- O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma.Brain : a journal of neurology · 2023Article
- Blood Clotting Dissolution in the Presence of a Magnetic Field and Preliminary Study with MG63 Osteoblast-like Cells-Further Developments for Guided Bone Regeneration?Bioengineering (Basel, Switzerland) · 2023Article
- Platelet-targeted thrombolysis for treatment of acute ischemic stroke.Blood advances · 2023Article
- A Fibrinogen-Mimicking, Activated-Platelet-Sensitive Nanocoacervate Enhances Thrombus Targeting and Penetration of Tissue Plasminogen Activator for Effective Thrombolytic Therapy.Advanced healthcare materials · 2022Article
- A novel ex vivo approach for measuring plasminogen activation upon established plasma clots.Research and practice in thrombosis and haemostasis · 2022Article
- "Going with the flow" in modeling fibrinolysis.Frontiers in cardiovascular medicine · 2022Review
- A Novel Mouse Model for Cerebral Venous Sinus Thrombosis.Translational stroke research · 2021Article
- Microbial Fibrinolytic Enzymes as Anti-Thrombotics: Production, Characterisation and Prodigious Biopharmaceutical Applications.Pharmaceutics · 2021Review
- Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.Science advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this work was to develop a high throughput assay for testing in vitro the thrombolytic activity using citrated whole blood samples, and to overcome the limitations of currently available techniques. We successfully developed a method that involves forming halo shaped, tissue factor induced, whole blood clots in 96 well plates, and then precisely measuring the thrombolysis process with a spectrophotometer plate reader. We here describe the implementation of this novel method, which we refer to as halo assay, and its validation with plasmin, urokinase and tissue plasminogen activator at different doses. The resulting data is a highly detailed thrombolysis profile, allowing comparison of different fibrinolytic agents. The time point analysis allows kinetic data to be collected and calculated to determine key parameters such as the activation time and the rate of fibrinolysis. We also assessed the capacity of the model to study the effect of clot maturation time on the fibrinolytic rate, an aspect of thrombosis rather unexplored with currently available methods, but of increasing importance in drug development. This novel thrombolysis assay could be an extremely useful research tool; to study the complex process of thrombolysis, and a valuable translational clinical tool; as a screening device to rapidly identify hypo- or hyper-fibrinolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.